NGPod Global Limited

NGPod Global Limited was a United Kingdom-based medical device company, registered in Runcorn, that developed and marketed the NGPOD pH confirmation device. The product was designed to confirm the position of nasogastric tubes without requiring aspiration or user interpretation — two factors the company identified as contributing to the majority of Never Events in enteral feeding. By providing a pH-based confirmation method, NGPOD aimed to enable safer, faster enteral nutrition, combat inpatient malnutrition, and reduce complications and length of hospital stay. The company positioned its device as a solution to a clinical problem in which current practice delays essential nutrition and medication for the majority of patients whose nasogastric tubes are actually correctly placed. According to the company, NGPOD reduces the need for costly and time-wasting interventions by up to 60%, and its solution was already making an impact in more than 20 hospitals across the UK. The brand's messaging emphasised accelerating change so that all patients could benefit from safer and faster tube placement confirmation. NGPod Global Limited operated as a private company and appears to have been a single-product or product-focused medical device business. Its commercial activities included product supply, training and articles, a podcast (NGPodcast), and a mobile application (NGPod App), indicating an effort to support healthcare professionals beyond the physical device itself. The company's trading status changed dramatically when it ceased trading and was placed into Creditors' Voluntary Liquidation on 13 August 2026. Following this, the company stopped accepting new orders. Existing customers and healthcare professionals were directed to current safety and regulatory information, including an MHRA Device Safety Information notice concerning quarantine and disposal of all NGPod devices, and an NGPod Field Safety Notice dated 25 August 2026. Enquiries relating to the liquidation were directed to appointed liquidators at MHA Advisory Limited in London. As a result of the liquidation, NGPod Global Limited is no longer an active commercial entity. Its brand and product remain relevant primarily in the context of the safety notices and the wind-down of its operations. The company's history illustrates the challenges faced by small medical device firms in bringing safety-critical innovations to market and sustaining them through regulatory and commercial pressures.

NGPod Global Limited was a United Kingdom medical device company based in Runcorn. It developed the NGPOD pH confirmation device, a product intended to confirm the placement of nasogastric tubes without aspiration or user interpretation. The company's clinical rationale was that current practice harms the majority of patients whose nasogastric tubes are actually in the correct position, by delaying essential nutrition and medication. NGPOD was designed to reduce the need for costly and time-wasting interventions by up to 60% and to enable safer, faster enteral nutrition, thereby combating inpatient malnutrition and reducing complications and length of hospital stay. By the time of its public-facing communications, NGPod Global Limited reported that its solution was already making an impact in more than 20 hospitals across the UK. The company maintained a website with sections for products, resources, training and articles, a podcast called NGPodcast, and a mobile application called NGPod App. These offerings suggest an effort to support healthcare professionals with education and digital tools alongside the physical device. The company's fortunes changed when it ceased trading and was placed into Creditors' Voluntary Liquidation on 13 August 2026. Following the liquidation, the company stopped accepting new orders. Its website directed existing customers and healthcare professionals to current safety and regulatory information, including an MHRA Device Safety Information notice concerning quarantine and disposal of all NGPod devices, and an NGPod Field Safety Notice dated 25 August 2026. Enquiries relating to the liquidation were directed to appointed liquidators Andrew Duncan and Georgina of MHA Advisory Limited, 6th Floor, 2 London Wall Place, London EC2Y. The liquidation marked the end of NGPod Global Limited as an operating business. The brand's legacy is tied to its safety-critical product and the subsequent regulatory notices. The company's trajectory reflects the difficulties small medical device innovators can face in sustaining commercial operations after bringing a novel device to market.

• NGPod Global Limited ceases trading and is placed into Creditors' Voluntary Liquidation

• NGPod Field Safety Notice issued

• MHRA Device Safety Information issued for NGPod pH testing device

Enabling safer, faster enteral nutrition to combat inpatient malnutrition and reduce complications and length of hospital stay.

• NGPOD pH confirmation device

  A pH confirmation device that does not require aspiration or user interpretation, designed to confirm nasogastric tube placement and reduce Never Events.

• NGPod App

  A mobile application offered alongside the NGPOD device.

• NGPodcast

  A podcast produced by the company.

1. 1Home | NGPod Globalngpodglobal.com
2. 2NGPod Global Limited (United Kingdom) - Wikidatawikidata.org
3. 3MHRA Device Safety Information - NGPod pH testing devicegov.uk
4. 4NGPod Field Safety Noticeazuksappnpdsa01.blob.core.windows.net